![duopharma 로고이미지](/images/page/duopharma.png)
Malaysian pharmaceutical company Duopharma Biotech Berhad is a strategic partner that has secured the rights to our stem
cell therapy products in four Southeast Asian countries (Malaysia, Singapore, Brunei, and the Philippines).
View Website
![health 로고이미지](/images/page/health.png)
We and the University of Utah Cell Sheet Tissue Engineering Center (CSTEC) are developing a treatment
anti-fibrosis with a cell sheet using our high-purity stem cells.
View Website
![steminent 로고이미지](/images/page/steminent.png)
We are preparing to conduct clinical trials in Korea for Spinocerebellar Ataxia stem cell therapy
developed by Taiwanese stem cell company Steminent Biotherapeutics
View Website
![allele 로고이미지](/images/page/allele.png)
Allele Biotechnology, an American stem cell company that started joint research with our company in 2019,
has a unique technology to produce induced pluripotent stem cells with mRNA technology.
We are jointly developing cell therapy for the treatment of diabetes using induced pluripotent stem cell-derived beta cells.
View Website
![vita 로고이미지](/images/page/vita.png)
Vita Therapeutics, an American cell therapy company that we invested in 2021, is a venture company established based on
the technology developed at Johns Hopkins University in the United States.
View Website
![pbs 로고이미지](/images/page/pbsbiotech.png)
We and PBS Biotech are developing a mass production process using a 3D bioreactor for cell therapy.
View Website
![handok 로고이미지](/images/page/handok.png)
We have signed a technology transfer contract for atopic dermatitis stem cell treatment with Handok,
and phase 3 clinical trials and product approval are scheduled to be carried out at Handok.
View Website